|Synonyms||Trimexolone; Org 6216; 11β-Hydroxy-16α,17α,21-trimethylpregna-1,4-dien-3,20-dione|
|Elimination half-life||estimated 1–2 hours|
|Chemical and physical data|
|Molar mass||370.525 g/mol|
|3D model (JSmol)|
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.
The substance is contraindicated in herpes simplex and most other viral eye infections, as well as mycobacterial, fungal and amoebal eye infections because it only reduces the inflammation but does not act against such microorganisms.
The most common adverse effects are blurred vision, tearing and other kinds of eye discomfort. Eye pain, eye oedema, headache, increased intraocular pressure and other side effects are seen in less than 1% of patients.
A small amount of rimexolone is absorbed into the systemic circulation. On hourly treatment with the eye drops for a week, blood serum concentrations peaked at 150 pg/ml on average, with many patients remaining below the detection threshold of 80 pg/ml. The elimination half-life from the circulation is estimated at one to two hours; the substance is mainly (over 80%) excreted via the faeces.
- Kavuncu S, Horoz H, Ardagil A, Erbil HH (August 2008). "Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery". Int Ophthalmol. 28 (4): 281–5. doi:10.1007/s10792-007-9131-0. PMID 17762913.
- Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Vexol 1% (10 mg/ml)-Augentropfensuspension.
- Drugs.com: Monograph.